Comprehend the growing market need and opportunity for a longer-acting insulin drug(s), or 3. Have the foresight to assess the impact that one or several catalysts could have on the price of Antriabio stock in 2013. Among other catalysts that could ignite shares of this emerging diabetes-drug maker, presentations at scientific meetings, peer-reviewed publications, and initiation of a human clinical study in the second quarter of this year, AntriBio could become the focus of M&A activity, as titans like Novo Nordisk (NVO) see the FDA reprimand and reject a thrice-weekly basil insulin over safety concerns. Investors may recall that a bidding war erupted over Amylin last year, culminating in a $7 Billion+ takeover by Bristol Myers Squibb (BMS). Amylin's long-acting GLP-1 product(s), a market notably smaller than basil insulins, had sparked the takeover frenzy.